Evidence map›Paper›PMID 39770553›Full record

ReviewPharmaceuticals (Basel, Switzerland)2024

RETRACTED: Nanotechnology for Healthcare: Plant-Derived Nanoparticles in Disease Treatment and Regenerative Medicine.

Arun Karnwal, Amar Yasser Jassim, Ameer Abbas Mohammed, Vikas Sharma, Abdel Rahman Mohammad Said Al-Tawaha, Iyyakkannu Sivanesan

RetractedAbstract readReviewRetracted Publication
In one paragraph

Review in Pharmaceuticals (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 43 papers.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Green-synthesizedRSC advances · 2026
    Article
  9. Polymers · 2026
    Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Phytofabrication of Zinc Oxide Nanoparticles UsingBioinorganic chemistry and applications · 2026
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Arun KarnwalDepartment of Microbiology, Graphic Era (Deemed to be University), Dehradun 248009, India.ORCID 0000-0001-6514-5647
Amar Yasser JassimDepartment of Marine Vertebrate, Marine Science Center, University of Basrah, Basrah 61001, Iraq.ORCID 0000-0002-4938-2156
Ameer Abbas MohammedDepartment of Marine Vertebrate, Marine Science Center, University of Basrah, Basrah 61001, Iraq.ORCID 0000-0001-7439-6229
Vikas SharmaDepartment of Molecular Biology and Genetic Engineering, School of Bioengineering and BioSciences, Lovely Professional University, Phagwara 144411, India.ORCID 0000-0003-1781-1056
Abdel Rahman Mohammad Said Al-TawahaDepartment of Biological Sciences, Al Hussein Bin Talal University Ma'an, Ma'an P.O. Box 20, Jordan.ORCID 0000-0001-5726-4363
Iyyakkannu SivanesanDepartment of Environmental Health Science, Institute of Natural Science and Agriculture, Konkuk University, Seoul 05029, Republic of Korea.ORCID 0000-0001-7447-6392

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nanotechnology has revolutionised biomedical research, offering innovative healthcare solutions. Plant-based nanotechnology is emerging as a sustainable alternative, minimising environmental impacts and enhancing therapeutic effectiveness. This paper explores the potential of plant-derived nanoparticles (PNPs) in medicine, highlighting their biocompatibility, multifunctionality, and eco-friendliness. PNPs, synthesised through green methods, have demonstrated promising applications in drug delivery, cancer therapy, antimicrobial treatments, and tissue regeneration. Their unique properties, such as a high surface area and bioactive components, enable improved drug delivery, targeting, and controlled release, reducing side effects and enhancing treatment efficacy. Additionally, plant-derived compounds' inherent antimicrobial and antioxidant properties, retained within platinum nanoparticles (PNPs), present innovative opportunities for combating antimicrobial resistance and promoting wound healing. Despite their potential, challenges remain in standardising PNP synthesis, ensuring consistency, and scaling up production for industrial applications. This review emphasises the need for further research on PNP toxicity, biocompatibility, and regulatory frameworks to fully harness their capabilities in clinical and commercial applications. Plant-based nanotechnology represents a promising, greener alternative for advancing healthcare solutions, aligning with global sustainability goals.

Indexed as

antimicrobial propertiesbiocompatibilitynanomedicineplant-derived nanoparticles (PNPs)sustainabilitytargeted drug delivery

Identifiers

PMID39770553
PMCPMC11678348

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.